Trelegy Ellipta, as a triple inhalation formulation, requires targeted prevention and control of its side effects based on the characteristics of the drug ingredients. The following is an explanation from three aspects: common side effects, serious adverse reactions, and mitigation measures.

1. Common side effects

(1) Respiratory reactions: including throat irritation, coughing, and hoarseness, with an incidence rate of about 15% -20%.

(2) Oral candidiasis: characterized by white spots or pain in the mouth, related to inhaled corticosteroids.

(3) Headache: It often occurs in the early stages of treatment and usually subsides after 1-2 weeks.

2. Serious adverse reactions

(1) Bronchospasm: Rare but alarming, characterized by sudden difficulty breathing and wheezing.

(2) Cardiovascular effects: May cause increased heart rate or arrhythmia, especially in patients with underlying heart disease.

(3) Adrenal suppression: Long term high-dose use may lead to a decrease in cortisol levels.

3. Mitigation and prevention measures

(1) Rinse mouth after medication: Rinse mouth thoroughly and spit out after each inhalation to reduce the risk of Candida infection.

(2) Inhalation technique training: Use a specialized trainer to ensure correct inhalation and reduce local irritation.

(3) Symptom monitoring: Regularly check lung function and oral mucosa, and assess blood pressure if persistent headaches occur.

(4) First aid preparation: Prepare quick acting bronchodilators to deal with possible bronchospasm attacks.

(5) Drug interactions: Avoid combination with potent CYP3A4 inhibitors (such as ketoconazole) as they may enhance systemic effects.